The relationship between hepatitis B virus (HBV) and the prognosis of hepatocellular carcinoma (HCC) after surgery remains uncertain. A retrospective cohort study was performed to evaluate the impact of pre-S deletions, T1762/A1764, and A1896 mutations on prognosis of HCC after curative resection. A total of 113 patients with positive serum HBV DNA (>200 IU/mL) who had underwent curative resection of pathologically proven HCC were recruited to determine the risk factors affecting the prognosis.
Introduction
Hepatocellular carcinoma (HCC) is a worldwide health threat, as it is the fifth most common malignant tumor and the third-place cancer associated death. [1] Etiologically, over half HCC occurs in chronic hepatitis B virus (HBV) infected subjects, especially in East Asia and sub-Saharan Africa, where HBV infection is highly popular. [2, 3] For these HCC cases, curative surgery was commonly considered the most effective treatment and the prognosis of HCC had been greatly improved during past decades. Nevertheless, high incidence of postoperative recurrence remains a major hindrance for making further improvement of the postoperative prognosis in HCC subjects. A previous study has documented that the postoperative tumor recurrence incidence at 3 years was calculated to be 39% in men and 37% in women who had underwent curative HCC tumor surgery. [4] It has been speculated that 2 different mechanisms were related with tumor intrahepatic recurrence, including intrahepatic metastasis and de novo multicentric carcinogenesis. [5, 6] The latter is distinct from the primary tumor clones. [7] However, majority of previous studies mainly aimed on the traditional potentially risk factors associated with intrahepatic metastasis, such as tumor size, nodule number, a positive surgical margin, TNM stage, macroscopic vascular invasion, and Edmondson grade. [8] [9] [10] In theory, it is probable that viral replication and integration of sub-genomic HBV DNA fragments into the host liver cells might play a key role in contributing to the process of carcinogenesis. [11, 12] Recently, the pathogenesis of HCC in HBV infection has been extensively investigated, and several viral risk factors have been ascertained, including seropositivity of hepatitis B e antigen (HBeAg), high serum levels of hepatitis B surface antigen (HBsAg), and HBV DNA, certain viral genotype, C1653T mutation in the enhancer II, T1753V mutation, and A1762T/G1764A double mutations in basal core promoter (BCP), and pre-S deletions. [13] [14] [15] [16] [17] However, the relationship between such viral factors with tumor recurrence after surgery have not been discussed comprehensively and so far little was known of the significance of the virologic status of patients with prognosis after resection of HCC, perhaps in part owing to the lack of interest in hepatitis virology among liver surgeons who handled these patients. The role of viral status in prognosis of HCC after curative resection remains uncertain and controversial.
As we known, the lower reach of Yangtze River is one of the highest endemic regions for chronic HBV infection and HCC in China. In a previous study, we have reported that serum HBV DNA level ≥10 4 copies/mL at tumor resection was independently associated with HCC recurrence in a retrospective cohort with a median follow-up period of 33.7 months after surgery. [18] Based on this result, we further planed to conduct this cohort study to assess the effect of viral status, especially certain viral mutations in pre-S and BCP regions, on the prognosis of HCC among patients who receiving curative surgery.
Methods

Study patients
Between January 2010 and December 2012, 113 patients with HBV-related HCC who underwent curative resection as primary therapy in the Affiliated Hospital of Nantong University were recruited in this retrospective cohort based on the following inclusion criteria: positive serum HBsAg for at least 12 months with positive serum HBV DNA (>200 IU/mL); all tumor nodules were completely removed with a surgical free margin of at least 5 mm by pathological inspection; absence of portal vein tumor thrombus (in main trunk or major branches), no cancerous thrombus found in hepatic veins or bile duct; 3 tumor nodules; absence of extrahepatic metastasis; no adjuvant antiviral therapy was given before or after the operation; death in the hospital not due to postoperative hepatic failure; and presence of early recurrence at least 3 months postoperatively (in order to exclude preoperative metastases). Maximal tumor size, nodule number, liver cirrhosis, capsular formation around the tumor, microvascular invasion, histological grade proposed by Edmondson and Steiner, and extent of resection were also determined. Serum samples collected before surgery were stored at À70°C before analysis. The protocol was approved by the Ethics Committee of the Affiliated Hospital of Nantong University in accordance with the tenets of the Declaration of Helsinki (date of approval, May 18, 2009; permission code, 2,009,025).
Follow-up and treatment for tumor recurrences
After surgical resection of HCC, all 113 patients were assessed every 3 to 6 months with dynamic contrast-enhanced computer tomography (CT) and/or magnetic resonance imaging (MRI), as well as with measurement of a serum tumor marker such as AFP. Hepatic angiography was performed when recurrence was suspected in only 1 patient according to strong personal requirement. In this case, the tumor recurrence was finally confirmed by elevated serum AFP level and typical image in CT examination 3 months after hepatic angiography. The identification of intrahepatic recurrence was based upon histopathologic examination of tumor tissue in 17 patients receiving second time tumor resection and on the typical imaging features on CT and MRI in 50 patients. No included patients received liver transplantation. Once recurrence was detected, patients obtained most suitable therapy on the basis of the location and number of recurrent nodules and hepatic function. Treatment of HCC recurrence contained a second time tumor resection, transcatheter arterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy, percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), and chemotherapy or radiotherapy.
Evaluation of prognostic clinicopathological factors
All clinicopathological factors of present study were enrolled for their potential relevance to the prognosis based on previous studies, including sex (man vs woman), age, alanine aminotransferase (ALT), albumin, total bilirubin, prothrombin time, HBeAg status (positive vs negative), serum HBV DNA ( 2000 vs >2000 IU/mL), serum AFP level ( 400 vs >400 ng/mL), coexisting hepatitis C virus ( . PCR reaction was carried out in 50 mL containing 5 mL 10Â buffer, 4 mL 2.5 mmol/L deoxynucleoside triphosphates (dNTP), 2 mL 10mmol/L sense and antisense primers, 1.5 U PlatinumTaq DNA polymerase (Invitrogen, Shanghai, China). First-round PCR was performed as follows: 95°C for 2 minutes; 95°C for 30 seconds, 56°C for 30 seconds, and 68°C for 3 minutes for 35 cycles; and finally, 68°C for 10 minutes. Two microliter of the first-round PCR product was reamplified by the same PCR condition as the first-round reaction. Second-round PCR primers were 5 0 -GTGCACTTCGC TTCACCTCT-3 0 (nt 1579-1598) and 5 0 -TCCACAGAAGCTCC GAATTC-3 0 (nt 1941-1922). For pre-S region sequence analysis, pre-S genes were amplified under the same PCR condition described above, except the primers were used. First-round PCR primers were 5 0 -AAAATTAATTATCCTGCTAGG-3 0 (nt 2627-2647) and 5 0 -GAGAAGTCCACCACGAGTC-3 0 (nt 269-251). Second-round PCR primers were 5 0 -TTTACAACTCTGTG-GAAGGC-3 0 (nt 2747-2766) and 5 0 -GAGTCTAGACTCTGTG GTATTGTG-3 0 (nt 255-232). All required prophylactic measures to prevent cross-contamination were taken, and negative controls were comprised in each run. Both strands of amplified products were directly sequenced by using an ABI 3700 sequencer and commercial kit (Applied Biosystems, Foster City, CA). Sequences analysis of the genome and deduced amino acid sequences were aligned and compared with the software MEGA version 4.1.
Identification of HBV genotype and mutations
HBV genotypes were determined by comparing the sequence of BCP/PC and pre-S regions with a set of standard sequences obtained from GenBank. HBV nucleotide sequences were aligned with the Clustal X software program and the phylogenetic trees were constructed by software MEGA version 4.1 software, as described previously. [16, 17] Li-Shuai et al. 
Statistical analysis
Data values were expressed as proportions, means ± SD, and median (range). Clinical and pathological data at the time of resection were analyzed to identify factors that influenced the prognosis by the Cox proportional hazards model. The overall survival was analyzed from the date of surgery to the date of last follow-up or death. The cumulative recurrence was analyzed from the date of surgery to the date of recurrent tumor detection, if HCC recurrence was not detected within the time of follow-up, the patients were censored on the last date of followup or the date of death. Survival curves were calculated by the Kaplan-Meier method and differences were statistically compared using the Log-Rank test. Multivariate analysis was performed by the Cox proportional hazards regression model to identify the independent factors on HCC prognosis. Two-tailed P values of <.05 were considered as statistically significant. All statistical analyses were performed using the Statistical Program for Social Sciences (SPSS v17.0 for Windows; SPSS, Inc., Chicago, IL).
Results
Sixty seven patients (59.3%) had intrahepatic tumor recurrence during the median observation period of 36.5 months (range, 3-72 months). Among these recurrent cases, 34 received TACE, 17 underwent a repeat tumor resection, 6 received RFA, 5 received postoperative radiotherapy or chemotherapy or PEI, and the reminder accepted a supportive therapy, respectively. Fifty eight patients died during the follow-up duration. Among them, 19 patients without HCC recurrence died from other reasons, mainly containing esophageal-gastric varices bleeding and chronic hepatic failure. In these unrecurrence related death, 10 died of gastrointestinal bleeding (2 with pre-S deletions, 8 with wild type), 7 hepatic failure (1 with pre-S deletions, 6 with wild type), and 2 brain hemorrhage (1 with pre-S deletions, 1 with wild type). The 1-, 3-, and 5-year overall survival rates after curative surgery in this study were 93.7%, 61.0%, and 42.5%, respectively. Meanwhile, the 1-, 3-, and 5-year cumulative recurrence rates after curative surgery were 18.0%, 49.7%, and 70.3%, respectively. The baseline demographic, clinicopathological, and virologic features of this retrospective cohort study were listed in Table 1 . Moreover, there was no significant difference between patients with pre-S deletions (n = 33) and patients with wild type infection (n = 80) in terms of these features (data not shown (Table 2) . Among 67 recurrence patients, 26 (38.8%) had pre-S deletion at the time of tumor resection. While, 7 (15.2%) of 46 non-recurrence patients had pre-S deletion (P = .007). Patients with pre-S deletion had significantly higher cumulative recurrence rates compared with those with wild type infection (P = .015; Fig. 1 ). In multivariate analysis, tumor size >3 cm in diameter (HR: 1.827, 95% CI: 1.052-3.174, P = .032), the presence of microvascular invasion (HR: 1.929, 95% CI: 1.114-3.340, P = .019) and pre-S deletion (HR: 1.781, 95% CI: 1.065-2.976, P = .028) were independent risk factors for tumor recurrence ( Li com were not statistically associated with the survival (Table 3) . The overall survival rates in group without pre-S deletion were higher than that in the patients with pre-S deletion mutation, but the difference was not significant (P = .230; Fig. 2 ). In multivariate analysis, the presence of microvascular invasion (HR: 2.035, 95% CI: 1.160-3.572, P = .013) and BCLC stage B or C (HR: 1.085, 95% CI: 1.066-3.059, P = .010) were independent risk factors for overall survival (Table 3) .
Deletion patterns in the pre-S region
Similar to our previous study, [16] the position and size of pre-S deletions were depicted in Table 4 . Of these 33 patients with pre-S deletions, the deletion pattern could be divided into 5 major types on the basis of the deletion site: type I (4 patients; pre-S1 deletions [5 0 terminus predominant; range from aa 1 to 57]); type II (5 patients; pre-S1 deletions [3 0 terminus predominant; range from aa 58 to 119]); type III (16 patients; pre-S2 deletions only); type IV (2 patients; deletions spanning both pre-S1 and pre-S2 regions; type V [2 patients; deletion at 2 diverse locations, one in the pre-S1 and the other in the pre-S2 separately]); and combined deletion type (4 patients). Overall, the number of pre-S nucleotide deletions altered from 15 to 86 bps. HBV pre-S deletions were found to be primarily clustered in the N-half of pre-S2 region (16 [48.5%] of 33). Pre-S deletions were more frequently detected in the pre-S2 domain coding amino acids 120 to 142. Loss of pre-S2 start codon was detected in 4 subjects (12.1%). Genotype C (30/ 33, 90.9%) dominated the HBV isolates with pre-S deletions in this cohort (Table 4) . We also analyzed the correlation of pre-S deletion types and tumor prognosis in the subgroup with pre-S deletions. For the limited patients with pre-S deletions (33 patients) in this cohort, we divided this subgroup into type III (16 patients) and other types (17 patients) deletions. The data showed that the patients with type III deletion had significant higher tumor recurrence rates than other deletion types (HR: 2.211, 95% CI: 1.008-4.846, P = .048). However, we did not observer the significant difference in overall survival rates between patients with type III and other types deletions (HR: 1.170, 95% CI: 0.494-2.769, P = .721). 
Functional domains potentially related to HCC-related pre-S deletions
To explore the possible effect of pre-S deletions on the viral function, we further analyzed the specific modes of all HCC postoperative recurrence involved pre-S deletions. Evidently, we found that the genome location spanning from the 3 0 -terminal half of pre-S1 to the 5 0 -terminal half of pre-S2 looked like to be the favorite target position of these deletions. Some wellinformed T-and B-cell epitopes overlap with this area. Epitope mapping of our 33 pre-S deletion mutations revealed that most of the deletion regions encompassed T and B-cell epitopes. Of them, the deletions in B-cell epitope coding amino acids from 120 to 145 were most frequently detected (66.7%, 22 of 33), followed by the T-cell epitope coding amino acids from 140 to 149 (57.6%, 19 of 33). Additionally, we further observed which of the well-informed functional sites of HBV genome were possibly involved by these deletions. Functional mapping of these pre-S deletion sequences showed that most of such deletion mutation types lost ≥1 important functional sites. The domains most usually involved were the transactivator domain in pre-S2 (TD-2, aa 120-172, 23 of 33, 69.7%), and the polymerized human serum albumin binding site (PHSA, aa 122-135, 21 of 33, 63.6%), followed by the nucleocapsid binding site (NBS, aa 107-127, 13 of 33, 39.4%), and heat shock protein 70-binding site (HSC70, aa 74-118, 11 of 33, 33.3%) ( Table 5 ).
Discussion
The prognosis of HCC is still not satisfactory, although it has been greatly enhanced in the past decades. Even after curative HCC resection, the incidence of postoperative tumor recurrence remains extremely high. [19] It has been reported that tumor size, vascular invasion, and intrahepatic metastasis were related significantly to predict HCC recurrence. [8, 10, [20] [21] [22] Meanwhile, the linkage between serum HBV DNA levels, status of HBsAg and HBeAg, certain viral genotypes, and specific viral sequence mutations and the risk of HCC development has been extensively confirmed. Despite convincing results supplied by previous Table 3 Factors identified on univariate and multivariate Cox regression analysis that influenced overall survival in HCC patients undergoing curative resection. According to prior published documents, there are strong and adequate proofs that high serum HBV DNA levels was associated with an increased risk of tumor recurrence in the remaining liver in HCC patients who underwent curative resection. [23] [24] [25] [26] However, there has been only a few of studies aiming at the viral mutations in patients receiving HCC resection. Based on our previous findings of HBV risk in the HCC development, the present cohort focused primarily on the linkage between classical HBV sequence mutations and the prognosis of HCC after curative resection. Our data distinctly revealed that tumor size >3 cm in diameter, the presence of microvascular invasion, and pre-S deletions were independent risk factors for postoperative recurrence. Additionally, other typical hot spot mutations comprising of the presence of A1896 mutation and T1762/ A1764 double mutations were not significantly associated with HCC prognosis. However, the current study did not show a significant effect of pre-S deletion on the overall survival rates for this retrospective recruited cohort. In the subgroup analysis, we further indicated that the patients with pre-S deletions had significant lower rate of dying from other reasons but not tumor recurrence than those with wild type infection, mainly comprising chronic deterioration of hepatic function and severe complications of advanced liver disease (4/33 vs 15/80, P < .05). We speculated that the distribution of un-recurrence related deaths in different groups might explain the discrepant effect of pre-S deletions on overall survival and tumor recurrence. Till date, present knowledge with regard to the role of certain HBV sequence mutations in HCC prognosis after surgery remains limited and controversial. At the beginning of the 20th century, Kubo et al [27] first described that the possibility of HCC recurrence after hepatic resection in cases with G1896A was statistically lower than those with wild-type infection. But this Deletion mutations are divided into the following 5 types: type I, pre-S1 deletion (N-half predominant; range, aa 1-57); type II, pre-S1 deletion (C-half predominant; range, aa 58-119); type III, pre-S2 deletion only; type IV, border between pre-S1 and pre-S2 region; type V, deleted at 2 separated sites, one in the pre-S1 region, the other in the pre-S2 region.
Factors
Li-Shuai et al. Medicine (2017) 96:43
Medicine beneficial impact of G1896A mutation was not validated by the following researches carried out in Hong Kong and mainland of China. [24, 28] Meanwhile, prior studies had reported that BCP double mutations was related with significantly increased risk of HCC recurrence after curative hepatic resection. [24, 29] However, this high tumor recurrence risk caused by A1762T/G1764A double mutations was not certified by the study conducted by Wu et al. [25] In present retrospective cohort, A1896 mutation and T1762/A1764 double mutations were not correlated with either tumor recurrence or overall survival. Furthermore, as another common mutation in pre-S sequence, the impact of pre-S deletions has been widely discussed. Su et al [30] had indicated that HCC subjects harboring pre-S deletions suffered obviously higher risk of tumor recurrence and multivariate analysis showed pre-S deletion was one of the independent risk factors associated with postoperative recurrence. Nevertheless, the data from other studies performed in Taiwan and Korea did not verify the point that the presence of pre-S deletions was related with HCC postoperative intrahepatic recurrence. [31, 32] A potential reason for these discrepant findings may attribute to the distinct viral and clinical feature of the chronic HBV infection had been introduced in different geographical regions of the world and is increasingly related with genetic diversity of the viral infection. [33] Moreover, Yeh et al [29] had displayed that only HCC subjects with short inframe or rearrangement pre-S deletion patterns (<100 bp) demonstrated a lower recurrence-free survival after tumor resection and all short pre-S deletions situated in a particular region ranging from codon 107 to 141. In current study, we also attempted to analyze the location and sizes of pre-S deletions. The pre-S2 deletions displayed a higher frequency than pre-S1 deletions in HBV isolates among HCC recurrent patients. The region spanning from the 3 0 -terminal half of pre-S1 to the 5 0 -terminal half of pre-S2 appeared to be the favored location for these deletions. Some familiar T-and B-cell epitopes overlap within this position. Therein, the B-cell epitope encoding amino acids between 120 and 145 was most usually deleted, subsequently followed by amino acids from 140 to 149 at the T-cell epitope. Additionally, we have identified which of the important functional regions of viral sequence were possibly involved by these deletion mutations. The pre-S region is essential for mediating the attaching HBV virus to host hepatocytes and is crucial in interaction with the host immune responses. Such deletions may provide a convenience in allowing HBV mutations to escape from immune attack. Meanwhile, this region has Table 5 The distribution of HCC-related pre-S deletions in HBV functional domains. Li-Shuai et al. Medicine (2017) 96:43 www.md-journal.com overlapped 9 important functional sites in HBV genome. [34, 35] These regions were most frequently related with the transactivator domain in pre-S2 (TD-2, aa 120-172), and followed by the polymerized human serum albumin binding site (PHSA, aa 122-135) in our study. It has been documented that functional damage of PHSA binding induced by pre-S deletions might lead to viral immaturities and create mutation viruses harboring changed envelope proteins. [36] Such mutant or immature viral particles may tend to be retained intracellularly, formation of ground glass hepatocytes, inducing endoplasmic reticulum stress, oxidative DNA impairment and overall genomic instability, which may cause eventually hepatocarcinogenesis. [37] [38] [39] Our opinion of this connection between pre-S deletions and HCC progression had also been verified by animal experiments, in which transgenic mice embodying pre-S2 mutation plasmids have been prone to induce dysplastic variants in hepatocytes and subsequent liver cancer. [40] In addition, tumor size and microvascular invasion were confirmed as independent risk factors affecting postoperative recurrence. Meanwhile, the presence of microvascular invasion and BCLC stage B or C were independently associated with poor overall survival after surgery. These findings were similar to that described previously. [41, 42] The strengths of present study included that we only enrolled HBV related-HCC patients after curative resection not experiencing antiviral therapy in this retrospective cohort, and thus these data are important in clarifying the impact of viral sequence mutation on tumor recurrence in the natural course of HBV. There are also several limitations of the current study that should be noticed. First of all, for the limited number of subjects with genotype B infection in population of this area, it is difficult to evaluate the risk of different viral genotype in HCC prognosis. Second, the method of direct sequencing just displays the predominant viral strains in the host and it tends to underestimate the real mutation level in cases, for in most chronic HBV carriers, mixed infection of multiple viral strains is common. Third, because of the detection limit of our nested PCR assay, we just recruited patients with positive serum HBV DNA into our study, it tends to underestimate rather than overestimate the risk of viral load. Fourth, we found that many included patients received conservative drug therapy several months before tumor resection, such as diuretic, albumin, plasma, and cryoprecipitate and prothrombin complex. After above treatment, some Child-Pugh grade B patients could achieve preoperative grade A. Unfortunately, all demographic data of subjects in this study were examined within 1 week before the operation. It tends to underestimate the real degree of liver function damage by ChildPugh grade preoperation. Finally, as a retrospective cohort study, it is difficult to draw a firm conclusion and a large-scale, welldesigned prospective study with long-term follow-up should be performed in future.
Conclusion
In summary, by conducting this postoperative prognostic model, our study supported the opinion that pre-S deletions were related with recurrence after curative tumor resection. If the role of pre-S deletion in predicting HBV-related HCC prognosis after curative resection is further confirmed, this new potential biomarker could be incorporated into the HCC recurrence risk surveillance strategy. More sophisticated, larger population-based cohort studies may be required to elucidate this issue in future.
